Akeso’s independently developed injectable drug, AK150, has received approval to commence clinical trials for the treatment of advanced solid tumors. As the sole ILT2/ILT4/CSF1R tri-specific antibody currently in development worldwide, AK150 marks Akeso’s first tri-specific antibody drug candidate to advance to the clinical stage. The development of this innovative drug leverages Akeso’s cutting-edge AI-driven drug discovery R&D technology platform, alongside its proprietary Tetrabody multi-specific antibody technology platform.

ILT2, ILT4, and CSF1R are known to be highly expressed in a variety of solid tumors. Conventional single-target or dual-target drugs have encountered significant challenges in penetrating the immunosuppressive network within the tumor microenvironment. In contrast, AK150 is designed to block relevant immunosuppressive signals, enabling comprehensive pathway inhibition. It effectively breaks through macrophage-mediated immunosuppression, thereby enhancing the collaborative anti-tumor activity of immune cells. Preclinical studies in animal models have demonstrated AK150’s notable tumor-inhibitory effects, as well as a clear dose-response relationship.

In the wake of this announcement, Akeso’s stock price experienced a substantial surge, climbing over 10.90% to close at HKD 115 per share.